634 related articles for article (PubMed ID: 22512844)
1. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials.
Yap T; Ahmed HU; Hindley RG; Guillaumier S; McCartan N; Dickinson L; Emberton M; Minhas S
Eur Urol; 2016 May; 69(5):844-51. PubMed ID: 26525837
[TBL] [Abstract][Full Text] [Related]
3. Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study.
Ahmed HU; Dickinson L; Charman S; Weir S; McCartan N; Hindley RG; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Eur Urol; 2015 Dec; 68(6):927-36. PubMed ID: 25682339
[TBL] [Abstract][Full Text] [Related]
4. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU
Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750
[TBL] [Abstract][Full Text] [Related]
5. Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study.
Miah S; Eldred-Evans D; Simmons LAM; Shah TT; Kanthabalan A; Arya M; Winkler M; McCartan N; Freeman A; Punwani S; Moore CM; Emberton M; Ahmed HU
J Urol; 2018 Dec; 200(6):1235-1240. PubMed ID: 29940251
[TBL] [Abstract][Full Text] [Related]
6. Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes.
Qaoud Y; Herrera-Caceres JO; Bass R; Berjaoui MB; Tiwari R; Kenk M; Lajkosz K; Finelli A; Perlis N; Klotz L; Fleshner N
Urol Oncol; 2022 Jul; 40(7):343.e1-343.e6. PubMed ID: 35537905
[TBL] [Abstract][Full Text] [Related]
7. Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound.
Mortezavi A; Krauter J; Gu A; Sonderer J; Bruhin J; Reeve KA; Held L; Donati OF; Rupp NJ; Moch H; Sulser T; Eberli D
J Urol; 2019 Oct; 202(4):717-724. PubMed ID: 31042109
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
Shah TT; Kanthabalan A; Otieno M; Pavlou M; Omar R; Adeleke S; Giganti F; Brew-Graves C; Williams NR; Grierson J; Miah H; Emara A; Haroon A; Latifoltojar A; Sidhu H; Clemente J; Freeman A; Orczyk C; Nikapota A; Dudderidge T; Hindley RG; Virdi J; Arya M; Payne H; Mitra A; Bomanji J; Winkler M; Horan G; Moore CM; Emberton M; Punwani S; Ahmed HU
Eur Urol; 2022 Jun; 81(6):598-605. PubMed ID: 35370021
[TBL] [Abstract][Full Text] [Related]
9. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.
Valerio M; Dickinson L; Ali A; Ramachadran N; Donaldson I; Mccartan N; Freeman A; Ahmed HU; Emberton M
J Urol; 2017 Mar; 197(3 Pt 1):647-654. PubMed ID: 27697580
[TBL] [Abstract][Full Text] [Related]
10. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
[TBL] [Abstract][Full Text] [Related]
11. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
12. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
13. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial.
Ghai S; Finelli A; Corr K; Chan R; Jokhu S; Li X; McCluskey S; Konukhova A; Hlasny E; van der Kwast TH; Incze PF; Zlotta AR; Hamilton RJ; Haider MA; Kucharczyk W; Perlis N
Radiology; 2021 Mar; 298(3):695-703. PubMed ID: 33529137
[TBL] [Abstract][Full Text] [Related]
14. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
Orczyk C; Barratt D; Brew-Graves C; Peng Hu Y; Freeman A; McCartan N; Potyka I; Ramachandran N; Rodell R; Williams NR; Emberton M; Ahmed HU
J Urol; 2021 Apr; 205(4):1090-1099. PubMed ID: 33315505
[TBL] [Abstract][Full Text] [Related]
15. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
[TBL] [Abstract][Full Text] [Related]
17. Description of Surgical Technique and Oncologic and Functional Outcomes of the Precision Prostatectomy Procedure (IDEAL Stage 1-2b Study).
Sood A; Jeong W; Palma-Zamora I; Abdollah F; Butaney M; Corsi N; Wurst H; Arora S; Kachroo N; Hassan O; Gupta N; Gorin MA; Menon M
Eur Urol; 2022 Apr; 81(4):396-406. PubMed ID: 34872786
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study.
Nair SM; Hatiboglu G; Relle J; Hetou K; Hafron J; Harle C; Kassam Z; Staruch R; Burtnyk M; Bonekamp D; Schlemmer HP; Roethke MC; Mueller-Wolf M; Pahernik S; Chin JL
BJU Int; 2021 May; 127(5):544-552. PubMed ID: 33037765
[TBL] [Abstract][Full Text] [Related]
20. Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia.
Elterman D; Li W; Hatiboglu G; Relle J; Zorn KC; Bhojani N; Chin J
J Endourol; 2021 Apr; 35(4):497-505. PubMed ID: 32935575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
